Related Experiment Video
Updated: May 16, 2025
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Particles, Liquids, and Antiplatelets: Restarting Antiplatelets on Postintervention Day 3 or Later is Associated with
Pious D Patel1, Sanjana Salwi2, Georgios Sioutas2
1Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia , Pennsylvania , USA.
Background And Objectives:
Timing of restarting antiplatelet agents after middle meningeal artery embolization (MMAE) for chronic subdural hematoma (cSDH) is a topic of controversy. The aim of this study was to determine whether the timing of antiplatelet restart after MMAE for cSDH affects long-term radiographic and clinical outcomes.
Methods:
A multi-institutional, retrospective cohort study was performed using data from 4 academic medical centers that performed MMAE for cSDH from 2018 to 2023. Patients were prescribed an antiplatelet agent before MMAE were included. Variables included demographics, comorbidities, timing of the procedure and antiplatelet restart, baseline modified Rankin Scale, initial size of SDH, and embolic material used. Outcomes were thickness of SDH at short-term (2 weeks) and long-term (6 weeks) follow-ups, need for unplanned surgical evacuation, and modified Rankin Scale at 90 days.
Results:
Of 128 patients (78% male, median age 76 years [IQR 70-83]), 67 patients (52%) had their antiplatelet agent restarted postintervention. Patients who did not have their antiplatelet agent restarted experienced higher mortality (20% vs 5%, P = .038). Among patients with antiplatelet agent restarted postintervention, there was a significant correlation (R = -0.43, P = .025) between timing of antiplatelet restart and long-term SDH size change. Antiplatelet restart on postintervention day 3 or later was associated with improvement in long-term SDH thickness (β = -5.7 mm, s.e. 2.5, P = .034). This effect was observed in the particle-embolization subgroup (β = -8.3 mm, s.e. 3.2, P = .021), but not the liquid-embolization subgroup (β = 1.7 mm, s.e. 5.5, P = .773).
Conclusion:
There was a higher rate of mortality and decreased functional independence among patients who did not have their antiplatelet agent restarted after MMAE for cSDH. Among patients who did have their antiplatelet restarted, a restart date of postintervention day 3 or later was associated with a significant decrease in long-term SDH size.
More Related Videos
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Formation of the Platelet Plug
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:16Clot Retraction and Fibrinolysis
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:13Radiological Investigation III: Pulmonary Angiogram and PET Scan
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...